Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Cambridge Cognition forms scientific advisory board
(Sharecast News) - Digital brain health solutions developer Cambridge Cognition announced the creation of a scientific advisory board on Thursday. The AIM-traded firm said the board aimed to offer expert guidance and market insights, with a particular emphasis on emerging trends such as the incorporation of blood-based biomarkers, collaborative opportunities for computerised cognitive assessments, and the importance of diverse populations in clinical trials.
It said the board would also play a pivotal role in reviewing and advising on product strategies, scientific approaches, and evidence generation for regulatory and data strategies.
Comprising experts in CNS-related disorders, clinical development, and academia, the board would dedicated to advancing brain health initiatives.
Chaired by Liam Kaufman, vice president of clinical science and former CEO of Winterlight Labs, the board also included professor Judith Jaeger, PhD, bringing over 35 years of experience in neuropsychology and psychopathology.
Professor Jaeger serves as the owner and president of CognitionMetrics, offering consultancy services to the pharmaceutical industry and a distinguished academic career at Albert Einstein College of Medicine, New York.
Another notable member would be professor John Harrison, a cognition expert and chief scientific officer at Scottish Brain Sciences.
With more than 25 years of experience, professor Harrison had assisted numerous CNS drug development organisations and made significant contributions to Alzheimer's disease research and psychiatric indications, including the development of the Neuropsychological Test Battery (NTB).
Completing the trio of founding members would be Francesca Cormack, PhD, chief scientist at Cambridge Cognition.
"With the emergence of disease-modifying therapies for Alzheimer's disease and progress in many other conditions, as well as the evolution of digital cognitive assessments, the landscape for CNS clinical research is rapidly evolving," said chief executive officer Matthew Stork.
"Establishing the scientific advisory board underscores our dedication to advancing the alignment of emerging trends in the sector.
"The board aims to deepen our understanding of customer requirements, assisting us to adapt rapidly to the evolving landscape while expanding the capabilities of our solutions."
At 1444 GMT, shares in Cambridge Cognition Holdings were up 0.18% at 55.6p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
